

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Serial No.: 10/700,906  
Applicant: Benjamin OSHLACK et al.  
Filed: November 4, 2003  
Art Unit: 1615  
Examiner: Humera N. SHEIKH  
For: **TAMPER-RESISTANT ORAL OPIOID  
AGONIST FORMULATIONS**

Mail Stop: AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

October 1, 2009

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with Applicants' duty of disclosure under 37 C.F.R. § 1.56 and the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicants submit herewith copies of:

- (i) the Office Action issued on July 20, 2009, in U.S. Serial No. 10/700,861; and
- (ii) the Office Action issued on July 22, 2009, in U.S. Serial No. 10/689,866.

It is respectfully requested that the information in the Office Actions be considered in its entirety and made of record.


This Information Disclosure Statement is filed under 37 C.F.R. § 1.97(c), "before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application" and is accompanied by the authorization to charge the fee set forth in § 1.17(p) to our Deposit Account No. 50-0552. In the

event any additional fee is due or an overpayment has been made in connection with the filing of this Information Disclosure Statement, the Commissioner is hereby authorized to charge said fee or credit said overpayment to our Deposit Account No. 50-0552.

Respectfully submitted,

DAVIDSON, DAVIDSON & KAPPEL, LLC

By:

  
Oleg Ioselevich  
Reg. No. 56,963

DAVIDSON, DAVIDSON & KAPPEL, LLC  
Patents, Trademarks and Copyrights  
485 Seventh Avenue, 14<sup>th</sup> Floor  
New York, New York 10018  
(212) 736-1940